UGN-104

UGN-104 is UroGen Pharma's next-generation reformulation of JELMYTO - the company's mitomycin reverse thermal gel approved in the US since April 2020 for low-grade upper tract urothelial cancer (LG-UTUC) [2]. The pitch is reducing treatment burden: same drug, same delivery platform, higher-concentration lyophilized mitomycin formulation (licensed from medac) so patients need fewer instillations per course. The Phase 3 NCT06774131 trial is recruiting toward 70 patients with complete response rate (CRR) as the primary endpoint, single-arm design [1]. This isn't a swing-for-the-fences program; it's a label-iteration play on an asset that delivered $21.7M in Q1 2026 product sales, with full-year 2026 guidance of $97-101M [6]. The real near-term value driver for UroGen is Zusduri (UGN-102), which delivered $29.2M in Q1 2026 (109% QoQ growth) on the bladder cancer launch [6]. UGN-104 matters for franchise defense - specifically, getting a refreshed product approved before JELMYTO's orphan drug exclusivity expires around April 2027 [7]. If readout slips to 2027 as the timeline suggests, the franchise defense rationale weakens materially.

Not novel. UGN-104 is a next-generation lyophilized mitomycin formulation (licensed from medac) combined with UroGen's RTGel platform, intended as a successor to JELMYTO/UGN-101 [8]. JELMYTO was approved by FDA in April 2020 under NDA 211728 for low-grade upper tract urothelial cancer - tumors in the lining of the renal pelvis or ureter, anatomically distinct from bladder cancer despite our database collapsing both to 'Bladder Cancer' [2]. The Phase 3 study (NCT06774131) is single-arm, recruiting toward 70 patients, with complete response rate as the primary endpoint [1]. UroGen hasn't disclosed a breakthrough or fast track designation specifically for UGN-104. Original JELMYTO carried orphan drug designation for UTUC granting 7 years of market exclusivity, which expires approximately April 2027 [7]. UGN-104 likely inherits orphan eligibility since the indication is identical, but that's not publicly confirmed. Because this is a formulation iteration of an approved drug, the regulatory path is almost certainly 505(b)(2) (a regulatory shortcut that lets a drug reference existing safety and efficacy data from a previously approved product instead of running a full trial program from scratch), referencing the existing JELMYTO package. UroGen has not publicly guided a readout date. Notably, the sister program UGN-103 (bladder cancer, next-gen Zusduri) is further along - UroGen guided an NDA submission for UGN-103 in 2H 2026 with potential approval in 2027 [6]. UGN-104 is behind that pace. Given recruiting status, accrual completion likely runs into 2026 at the earliest, with a readout in 2027 - uncomfortably close to or after the JELMYTO orphan exclusivity sunset.

Mitomycin is a chemotherapy drug from the 1950s. It's an alkylating agent, meaning it crosslinks DNA so cancer cells can't replicate. Standard mitomycin gets washed out of the upper urinary tract by urine within minutes, which is why oncologists historically couldn't use it for upper tract tumors - the drug couldn't sit on the tumor long enough to do anything. UroGen's trick is the reverse thermal gel (RTGel): liquid when cold, solid when warm. The drug gets instilled as a chilled liquid through a ureteral catheter, then gels at body temperature, holding mitomycin in contact with the tumor for several hours before dissolving and being excreted. JELMYTO proved this works. The OLYMPUS trial reported a 59% complete response rate at the primary 3-month disease evaluation in patients whose only alternative was removing the kidney and ureter (nephroureterectomy), a morbid surgery that ends one of two kidneys' worth of function [3]. Durability at 12 months by Kaplan-Meier analysis was 84%, and longer-term follow-up reported a median duration of response of 47.8 months among the 41 patients who achieved complete response [9]. UGN-104 keeps the same drug class, same delivery platform, same disease, with a reformulated higher-concentration lyophilized mitomycin (medac partnership) designed to deliver an equivalent or better dose with fewer instillations [8]. Mechanism is validated. The bet is logistics, not biology.

NCT06774131 is a single-arm Phase 3, n=70, primary endpoint complete response rate (CRR) [1]. No randomization, no comparator drug. That's appropriate for a small disease where the original JELMYTO key (OLYMPUS) was also single-arm against a historical-control framing. The implicit comparator is JELMYTO itself: 59% CRR at 3 months with 84% 12-month Kaplan-Meier durability sets the benchmark UGN-104 needs to match or beat with a reduced dosing burden [3][9]. The broader clinical landscape matters too: for LG-UTUC, the real-world alternatives to JELMYTO are endoscopic laser ablation (kidney-sparing but recurrence-prone and not feasible for all anatomic locations in the upper tract) and nephroureterectomy (definitive but morbid). UGN-104's commercial case depends on converting urologists who currently default to ablation or surgery because the JELMYTO instillation burden is too high. Concerns on trial design are honest. Single-arm trials in small populations leave room for selection bias, and 70 patients gives limited statistical precision on safety signals - especially for ureteral stricture, which is the main on-target toxicity worth tracking. But for a 505(b)(2) bridge of an approved drug in an identical indication, FDA generally doesn't ask for randomized data. They want assurance the new formulation behaves comparably. Enrollment status is 'recruiting' as of the most recent ClinicalTrials.gov update. Pace matters here: LG-UTUC is rare (UTUC overall runs ~7,000 US cases/year, and only a subset are low-grade), so finding 70 eligible patients across willing sites is non-trivial. UroGen's clinical network from OLYMPUS and the Zusduri program is the operational advantage.

Our model gives this drug a 30% chance of eventually being approved. That figure starts from a historical baseline of about 48% for Phase 3 drugs in this area, then adjusts based on ten facts about the trial and sponsor. The main drags on the estimate are the sponsor's weak approval track record, limited earlier-phase results, and smaller-than-typical enrollment. One factor works in the drug's favor - a non-randomized trial design - but it isn't enough to offset the negatives.

Four real risks. First, ureteral stricture. JELMYTO at standard concentration causes ureteral narrowing in a meaningful fraction of patients, sometimes requiring stenting and occasionally contributing to kidney function loss [3]. A higher-concentration formulation could worsen this without proportionally improving efficacy, which would be the worst-case outcome. Second, the orphan exclusivity clock. JELMYTO's 7-year orphan drug exclusivity expires around April 2027 [7]. If UGN-104 doesn't have its own approval and exclusivity stamp before that window closes, the franchise defense rationale weakens - generic mitomycin RTGel competition becomes a live threat, and UGN-104 needs to deliver clear differentiation to justify premium pricing. With readout likely in 2027 and an NDA review cycle behind that, the timing is tight. Third, enrollment pace. UTUC is rare, low-grade UTUC rarer still. UroGen's footprint helps, but 70 patients still takes time, and the parallel Zusduri commercial launch and UGN-103 program likely pull clinical operations attention. Fourth, commercial cannibalization and pricing. UGN-104 mostly replaces JELMYTO rather than expanding the market. JELMYTO posted $21.7M in Q1 2026 with 2026 guidance of $97-101M [6]. UGN-104 either needs to defend that base at better unit economics (fewer instillations × higher net realization per instillation) or grow the prescriber population by reducing procedural burden enough to convert urologists who currently default to laser ablation or nephroureterectomy. UroGen has not publicly disclosed pricing strategy for UGN-104 vs JELMYTO.

Worth watching but not urgent. UroGen's near-term story is Zusduri (UGN-102) in bladder, and the launch is tracking ahead of expectations: Q1 2026 Zusduri revenue was $29.2M (109% QoQ growth, contributing to a 152% YoY total revenue jump to $51M) on the back of the permanent J-code effective January 2026 [6]. 972 activated sites of care and 256 unique prescribers as of March 31, 2026. UroGen ended Q1 2026 with $140.3M in cash and marketable securities (up from $120.5M at year-end 2025) and net loss narrowed to $23.6M, suggesting near-term runway is adequate to fund both Zusduri launch and pipeline progression without immediate dilution risk [6]. Against this backdrop, UGN-104 is franchise maintenance for JELMYTO, not the company-defining catalyst - but the JELMYTO orphan exclusivity sunset (~April 2027) makes the UGN-104 timeline genuinely load-bearing for the long-tail UTUC franchise [7]. Sister program UGN-103 (next-gen bladder) is ahead - NDA submission targeted 2H 2026, potential approval 2027 [6]. UGN-104 lags that schedule. The signal that would change my view: interim Phase 1/2 PK and safety data on UGN-104 showing the higher concentration doesn't increase ureteral stricture rates relative to historical JELMYTO. If that lands at an American Urological Association (AUA) meeting or a Society of Urologic Oncology (SUO) meeting, the Phase 3 readout becomes much more confident, and the bridge approval looks close to baked. Without it, the single-arm n=70 design will leave payers and the Institute for Clinical and Economic Review (ICER, which publishes influential drug cost-effectiveness assessments) with questions about whether UGN-104 is incremental enough to command pricing above JELMYTO. Check back when UroGen either (a) guides a readout window on an earnings call or (b) presents UGN-104 Phase 1/2 data at AUA or SUO.